258 results on '"Ebens, Christen L."'
Search Results
2. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity
3. Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa
4. Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa–Associated Cutaneous Squamous Cell Carcinoma
5. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
6. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
7. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD
8. Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium
9. The diagnosis of severe combined immunodeficiency: Implementation of the PIDTC 2022 Definitions
10. Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation
11. Interrogation of RDEB Epidermal Allografts after BMT Reveals Coexpression of Collagen VII and Keratin 15 with Proinflammatory Immune Cells and Fibroblasts
12. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC
13. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients
14. Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders
15. Liver disease and transplantation in telomere biology disorders: An international multicenter cohort.
16. Outcomes Following Matched Sibling Donor Transplant for Severe Combined Immunodeficiency: A Report from the Pidtc
17. Impact of High Dose Acyclovir Prophylaxis for the Prevention of Cytomegalovirus Reactivation after Pediatric Allogeneic Stem Cell Transplant
18. Defibrotide Prophylaxis after Second Hematopoietic Cell Transplant in Pediatric Patients at Very High Risk for Veno-Occlusive Disease
19. Detection and treatment of cerebral toxoplasmosis in an aplastic pediatric post-allogeneic hematopoietic cell transplant patient: a case report
20. Deconstructing progressive inflammatory fibrosis in recessive dystrophic epidermolysis bullosa
21. Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study
22. Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia
23. Characterizing Immune-Mediated Cytopenias After Allogeneic Hematopoietic Cell Transplantation for Pediatric Nonmalignant Disorders
24. Immune-Mediated Cytopenias After Hematopoietic Cell Transplantation: Pathophysiology, Clinical Manifestations, Diagnosis, and Treatment Strategies
25. Frequency of and Factors Influencing Vitamin C Levels in Pediatric Hematopoietic Cell Therapy Patients
26. Relevance of Monitoring Thymic Function and Recovery in Interpreting Immune Reconstitution Post Hematopoietic Cell Transplantation in Pediatric Patients with Inborn Errors of Immunity
27. Revisiting Pre-Transplant Testicular Radiation for Relapse Prophylaxis in Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL)
28. Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
29. Donor Derived Leukemia in a Recipient of Allogeneic Hematopoietic Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa
30. Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Reduced Intensity Conditioning with Cyclophosphamide/Fludarabine/Total Body Irradiation (TBI) with Tacrolimus, MMF, and Conditional Anti Thymocyte Globulin (ATG) for the Treatment of Hematological Malignancies
31. Revisiting the Role of Post-Transplant Central Nervous System Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
32. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increase Relapse Risk Compared to Historical Cyclosporine/ Methotrexate
33. Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands
34. Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
35. Relevance of Monitoring Thymic Function and Recovery in Interpreting Immune Reconstitution Post Hematopoietic Cell Transplantation in Inborn Errors of Immunity
36. Radiation Sparing Reduced Intensity Conditioning for Allogeneic Cell Transplantation in Patients with Dyskeratosis Congenita Comparable to Standard of Care: A Phase III Single Institution Trial
37. Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
38. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
39. 116 - Event Free Survival in Severe Combined Immune Deficiency (SCID) Infants after Conditioned Umbilical Cord Blood Transplantation (UCBT) Benefits from Omitting Serotherapy
40. Notch signaling in hematopoietic cell transplantation and T cell alloimmunity
41. Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD
42. 125 - Hematopoietic Cell Transplantation in 240 Patients with Chronic Granulomatous Disease: A Pidtc Report
43. Outcomes after Hematopoietic Cell Transplant and Gene Therapy for Adenosine Deaminase (ADA) Severe Combined Immune Deficiency: A Combined Analysis from the Primary Immune Deficiency Treatment Consortium (PIDTC) 6901 and 6902 Studies
44. Hematopoietic Cell Transplantation in 240 Patients with Chronic Granulomatous Disease: A Pidtc Report
45. Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis
46. Third-Party Virus-Specific T-Cell Infusion for the Treatment of Refractory Viral Infections: Results from PBMTC SUP1701
47. A Primary Immune Deficiency Treatment Consortium (PIDTC) Study of Chronic and Late Onset Medical Complications after Initial Hematopoietic Cell Transplantation (HCT) for Severe Combined Immunodeficiency Disease (SCID)
48. Revertant Mosaicism in Epidermolysis Bullosa
49. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
50. Isavuconazonium Sulfate Use in Multi-Modal Management of Invasive Mucormycosis in Four Pediatric Allogeneic Hematopoietic Cell Transplant Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.